Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 May 2016

Tsabari Reuven, Elyashar Hila Iron, Cymberknowh Malena Cohen, Breuer Oded, Armoni Shoshana, Livnat Galit, Kerem Eitan, Zangen David Haim

Abstract excerpt

OBJECTIVE: To investigate the effect of treatment with ivacaftor on insulin secretion in patients with cystic fibrosis (CF) (ΔF508\S549R) having CFRD/impaired insulin secretion. METHODS: A standard OGTT was performed before and after 16weeks of treatment with ivacaftor in 2 sibling patients with CF carrying the S549R gating mutation. The area under the curve (AUC) for glucose and insulin was calculated using the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Blood Glucose

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chloride Channel Agonists

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Insulin Secretion

Share to Quinolones

Share to Siblings

Source

Identifiers

PMID: 26547591
DOI: 10.1016/j.jcf.2015.10.012

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation.PMID 26547591Read ↗

Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.Semantic proximity Read ↗

Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study.Semantic proximity Read ↗

Islet-intrinsic effects of CFTR mutation.Semantic proximity Read ↗

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion.Semantic proximity Read ↗

Insulin production and resistance in cystic fibrosis: effect of age, disease activity, and genotype.Semantic proximity Read ↗

Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis.Semantic proximity Read ↗

Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor.Semantic proximity Read ↗

Changes in glucose tolerance in people with cystic fibrosis after initiation of first-generation CFTR modulator treatment.Semantic proximity Read ↗

Preservation of β-cell Function in Pancreatic Insufficient Cystic Fibrosis With Highly Effective CFTR Modulator Therapy.Semantic proximity Read ↗

Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes.Semantic proximity Read ↗

Glucose-Sensitive CFTR Suppresses Glucagon Secretion by Potentiating KATP Channels in Pancreatic Islet α Cells.Semantic proximity Read ↗

Glucose homeostasis and genotype-phenotype interplay in cystic fibrosis patients with CFTR gene deltaF508 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.